NMPA Pluvicto coverage for business development, investment, and market access teams
Novartis has reported stronger PSA responses with its drug Pluvicto in earlier-stage prostate cancer, indicating promising developments in oncology. This news could reshape competitive dynamics in the market.
We use cookies to enhance your experience, analyze traffic, and for marketing. By continuing to use our site, you consent to our use of cookies. Privacy Policy
